Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation

Journal of Immunology

Volumn 173, Issue 2, 2004, Pages 892-899

  Kemp, Troy J ^a,b   Moore, Jill M ^a   Griffith, Thomas S ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CYTOKINE; OLIGODEOXYNUCLEOTIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

EID: 3142757918     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.2.892     Document Type: Article

References (64)

1. Tokunaga, T., H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, T. Sudo, et al. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:955.
2. Yamamoto, S., E. Kuramoto, S. Shimada, and T. Tokunaga. 1988. In vitro augmentation of natural killer cell activity and production of interferon-β/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 79:866.
3. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709.
4. Kuramoto, E., O. Yano, Y. Kimura, M. Baba, T. Makino, S. Yamamoto, T. Yamamoto, T. Kataoka, and T. Tokunaga. 1992. Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83:1128.
5. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546.
6. Krieg, A. M. 1998. Leukocyte stimulation by oligodeoxynucleotides. In Applied Antisense Oligonucleotide Technology. C. A. Stein and A. M. Krieg, eds. Wiley, New York, p. 431.
7. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675.
8. Takeda, K., and S. Akira. 2001. Roles of Toll-like receptors in innate immune responses. Genes Cells 6:733.
9. Verthelyi, D., and R. A. Zeuner. 2003. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24:519.
10. Hartmann, G., J. Battiany, H. Poeck, M. Wagner, M. Kerkmann, N. Lubenow, S. Rothenfusser, and S. Endres. 2003. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33:1633.
11. Isaacs, A., and J. Lindenmann. 1987. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957. J. Interferon. Res. 7:429.
12. Luo, Y., X. Chen, T. M. Downs, W. C. DeWolf, and M. A. O'Donnell. 1999. IFN-α2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J. Immunol. 162:2399.
13. Kantarjian, H. M., M. J. Keating, E. H. Estey, S. O'Brien, S. Pierce, M. Beran, C. Koller, E. Feldman, and M. Talpaz. 1992. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J. Clin. Oncol. 10:772.
14. Gresser, I. 1990. Biologic effects of interferons. J. Invest. Dermatol. 95:66S.
15. Herberman, R. B., C. W. Reynolds, and J. R. Ortaldo. 1986. Mechanism of cytotoxicity by natural killer (NK) cells. Annu. Rev. Immunol. 4:651.
16. Lindahl, P., P. Leary, and I. Gresser. 1972. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc. Natl. Acad. Sci. USA 69:721.
17. Morikawa, K., H. Kubagawa, T. Suzuki, and M. D. Cooper. 1987. Recombinant interferon-α, -β, and -γ enhance the proliferative response of human B cells. J. Immunol. 139:761.
18. Vogel, S., D. Finbloom, K. English, D. Rosenstreich, and S. Langreth. 1983. Interferon-induced enhancement of macrophage Fc receptor expression: β-interferon treatment of C3H/HeJ macrophages results in increased numbers and density of Fc receptors. J. Immunol. 130:1210.
19. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189:1343.
20. Fanger, N. A., C. R. Maliszewski, K. Schooley, and T. S. Griffith. 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190:1155.
21. Zamai, L., M. Ahmad, I. M. Bennett, L. Azzoni, E. S. Alnemri, and B. Perussia. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 88:2375.
22. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189:1451.
23. Kemp, T. J., B. D. Elzey, and T. S. Griffith. 2003. Plasmacytoid dendritic cell-derived IFN-α induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171:212.
24. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z. K. Ballas, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2154.
25. Blackwell, S. E., and A. M. Krieg. 2003. CpG-A-induced monocyte IFN-γ-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-α. J. Immunol. 170:4061.
26. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835.
27. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919.
28. Martin, J. H., and S. W. Edwards. 1993. Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture: reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. J. Immunol. 150:3478.
29. +-ATPase, on CTL-mediated cytotoxicity. J. Immunol. 153:3938.
30. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch, and M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:2833.
31. Wang, Q., Y. Ji, X. Wang, and B. M. Evers. 2000. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem. Biophys. Res. Commun. 276:466.
32. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531.
33. + T cells by IFN-α. Clin. Exp. Immunol. 132:216.
34. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335.
35. Krieg, A. M., W. C. Gause, M. F. Gourley, and A. D. Steinberg. 1989. A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J. Immunol. 143:2448.
36. Krieg, A. M., J. Tonkinson, S. Matson, Q. Zhao, M. Saxon, L. M. Zhang, U. Bhanja, L. Yakubov, and C. A. Stein. 1993. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. USA 90:1048.
37. Wiemann, B., and C. O. Starnes. 1994. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64:529.
38. Weiner, G. I., H. M. Liu, J. E. Wooldridge, C. E. Dahle, and A. M. Krieg. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 94:10833.
39. Heckelsmiller, K., K. Rall, S. Beck, A. Schlamp, J. Seiderer, B. Jahrsdorfer, A. Krug, S. Rothenfusser, S. Endres, and G. Hartmann. 2002. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169:3892.
40. Heckelsmiller, K., S. Beck, K. Rall, B. Sipos, A. Schlamp, E. Tuma, S. Rothenfusser, S. Endres, and G. Hartmann. 2002. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32:3235.
41. Hafner, M., R. Zawatzky, C. Hirtreiter, W. A. Buurman, B. Echtenacher, T. Hehlgans, and D. N. Mannel. 2001. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 61:5523.
42. Lonsdorf, A. S., H. Kuekrek, B. V. Stern, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann. 2003. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol. 171:3941.
43. Stern, B. V., B. O. Boehm, and M. Tary-Lehmann. 2002. Vaccination with tumor peptide in CpG adjuvant protects via IFN-γ-dependent CD4 cell immunity. J. Immunol. 168:6099.
44. Hahne, M., T. Renno, M. Schroeter, M. Irmler, L. French, T. Bomard, H. R. MacDonald, and J. Tschopp. 1996. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:721.
45. Mariani, S. M., and P. H. Krammer. 1998. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28:973.
46. Mariani, S. M., and P. H. Krammer. 1998. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28:1492.
47. Eerola, A. K., Y. Soini, and P. Paakko. 1999. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer 26:73.
48. Tormanen-Napankangas, U., Y. Soini, and P. Paakko. 2001. High number of tumour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma. APMIS 109:525.
49. Nzula, S., J. J. Going, and D. I. Stott. 2003. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 63:3275.
50. Lanzavecchia, A. 1990. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8:773.
51. Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, and B. Hilliard. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191:1095.
52. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.
53. Brunner, T., N. J. Yoo, T. S. Griffith, T. A. Ferguson, and D. R. Green. 1996. Regulation of CD95 ligand expression: a key element in immune regulation? Behring Inst. Mitt. 97:161.
54. Jeremias, I., I. Herr, T. Boehler, and K. M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28:143.
55. Martinez-Lorenzo, M. J., M. A. Alava, S. Gamen, K. J. Kim, A. Chuntharapai, A. Pineiro, J. Naval, and A. Anel. 1998. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28:2714.
56. Bonfoco, E., P. M. Stuart, T. Brunner, T. Lin, T. S. Griffith, Y. Gao, H. Nakajima, P. A. Henkart, T. A. Ferguson, and D. R. Green. 1998. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9:711.
57. + dendritic cells. J. Immunol. 166:5000.
58. Kadowaki, N., S. Ho, S. Antonenko, R. W. Malefyt, R. A. Kastelein, F. Bazan, and Y. J. Liu. 2001. Subsets of human dendritic cell precursors express different Toll-Like receptors and respond to different microbial antigens. J. Exp. Med. 194:863.
59. Kerkmann, M., S. Rothenfusser, V. Hornung, A. Towarowski, M. Wagner, A. Sarris, T. Giese, S. Endres, and G. Hartmann. 2003. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170:4465.
60. Marie, I., J. E. Durbin, and D. E. Levy. 1998. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660.
61. De Maeyer, E., and J. De Maeyer-Guignard. 1998. Type I interferons. Int. Rev. Immunol. 17:53.
62. Hiscott, J., K. Cantell, and C. Weissmann. 1984. Differential expression of human interferon genes. Nucleic Acids Res. 12:3727.
63. MacDonald, N. J., D. Kuhl, D. Maguire, D. Naf, P. Gallant, A. Goswamy, H. Hug, H. Bueler, M. Chaturvedi, J. de la Fuente, et al. 1990. Different pathways mediate virus inducibility of the human IFN-α1 and IFN-β genes. Cell 60:767.
64. Hilkens, C. M., J. F. Schlaak, and I. M. Kerr. 2003. Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol. 171:5255.